PHAT
Price
$3.25
Change
-$0.05 (-1.51%)
Updated
May 14, 04:59 PM (EDT)
Capitalization
226.9M
85 days until earnings call
SYRE
Price
$14.85
Change
+$0.10 (+0.68%)
Updated
May 14, 04:59 PM (EDT)
Capitalization
889.06M
78 days until earnings call
Ad is loading...

PHAT vs SYRE

Header iconPHAT vs SYRE Comparison
Open Charts PHAT vs SYREBanner chart's image
Phathom Pharmaceuticals
Price$3.25
Change-$0.05 (-1.51%)
Volume$66.11K
Capitalization226.9M
Spyre Therapeutics
Price$14.85
Change+$0.10 (+0.68%)
Volume$32.17K
Capitalization889.06M
PHAT vs SYRE Comparison Chart
Loading...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PHAT vs. SYRE commentary
May 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PHAT is a Hold and SYRE is a Hold.

Ad is loading...
COMPARISON
Comparison
May 15, 2025
Stock price -- (PHAT: $3.31 vs. SYRE: $14.75)
Brand notoriety: PHAT and SYRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PHAT: 65% vs. SYRE: 147%
Market capitalization -- PHAT: $226.9M vs. SYRE: $889.06M
PHAT [@Biotechnology] is valued at $226.9M. SYRE’s [@Biotechnology] market capitalization is $889.06M. The market cap for tickers in the [@Biotechnology] industry ranges from $289.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PHAT’s FA Score shows that 0 FA rating(s) are green whileSYRE’s FA Score has 0 green FA rating(s).

  • PHAT’s FA Score: 0 green, 5 red.
  • SYRE’s FA Score: 0 green, 5 red.
According to our system of comparison, SYRE is a better buy in the long-term than PHAT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PHAT’s TA Score shows that 5 TA indicator(s) are bullish while SYRE’s TA Score has 4 bullish TA indicator(s).

  • PHAT’s TA Score: 5 bullish, 3 bearish.
  • SYRE’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, PHAT is a better buy in the short-term than SYRE.

Price Growth

PHAT (@Biotechnology) experienced а +37.92% price change this week, while SYRE (@Biotechnology) price change was +17.91% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.93%. For the same industry, the average monthly price growth was +6.80%, and the average quarterly price growth was -5.97%.

Reported Earning Dates

PHAT is expected to report earnings on Aug 07, 2025.

SYRE is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (+0.93% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SYRE($889M) has a higher market cap than PHAT($227M). SYRE YTD gains are higher at: -36.641 vs. PHAT (-59.236). SYRE has higher annual earnings (EBITDA): -214.36M vs. PHAT (-272.12M). SYRE has more cash in the bank: 565M vs. PHAT (212M). SYRE has less debt than PHAT: SYRE (0) vs PHAT (204M). PHAT has higher revenues than SYRE: PHAT (81.9M) vs SYRE (0).
PHATSYREPHAT / SYRE
Capitalization227M889M26%
EBITDA-272.12M-214.36M127%
Gain YTD-59.236-36.641162%
P/E RatioN/A1.72-
Revenue81.9M0-
Total Cash212M565M38%
Total Debt204M0-
FUNDAMENTALS RATINGS
SYRE: Fundamental Ratings
SYRE
OUTLOOK RATING
1..100
19
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
95
PRICE GROWTH RATING
1..100
64
P/E GROWTH RATING
1..100
81
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
PHATSYRE
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
86%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
MACD
ODDS (%)
Bullish Trend 2 days ago
89%
Bullish Trend 2 days ago
79%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bullish Trend 2 days ago
83%
Advances
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 3 days ago
85%
Declines
ODDS (%)
Bearish Trend 9 days ago
86%
Bearish Trend 9 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Ad is loading...
PHAT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SYRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FFNTX13.15N/A
N/A
Fidelity Advisor Asset Manager 40% M
MMYLX8.77N/A
N/A
MassMutual Small Company Val Adm
BTSMX24.73N/A
N/A
Boston Trust SMID Cap
FSUVX21.90N/A
N/A
Fidelity SAI US LowVolatility Idx
JIIGX76.26N/A
N/A
JPMorgan US Sustainable Leaders R6

PHAT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PHAT has been loosely correlated with TNFA. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if PHAT jumps, then TNFA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PHAT
1D Price
Change %
PHAT100%
+5.08%
TNFA - PHAT
39%
Loosely correlated
-8.83%
ATRA - PHAT
36%
Loosely correlated
+3.25%
IMTX - PHAT
35%
Loosely correlated
-4.82%
IRON - PHAT
34%
Loosely correlated
-0.56%
SYRE - PHAT
32%
Poorly correlated
-1.21%
More

SYRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SYRE has been loosely correlated with BEAM. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if SYRE jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SYRE
1D Price
Change %
SYRE100%
-1.21%
BEAM - SYRE
56%
Loosely correlated
-1.04%
APGE - SYRE
52%
Loosely correlated
+0.40%
IDYA - SYRE
52%
Loosely correlated
-4.90%
CGON - SYRE
52%
Loosely correlated
-3.90%
IMNM - SYRE
50%
Loosely correlated
-0.38%
More